BrightSpring boosts 2025 guidance as Pharmacy and Provider segments post strong gains and margin initiatives take hold.

Boston Scientific lifts its 2025 sales and EPS outlook after a strong Q1, with cardiology and EP segments fueling major gains.

AXON lifts 2025 EBITDA outlook as strong TASER and body cam sales drive margin gains despite rising costs.

PPC hit a 12% EBITDA margin in the first quarter of 2025, boosted by U.S. gains and strong pricing across key segments.

PPC hit a 12% EBITDA margin in the first quarter of 2025, boosted by U.S. gains and strong pricing across key segments.

TOST stock surges on 25% revenue growth and 32% EBITDA margin. It raises 2025 outlook as it scales with disciplined cost control.

TOST stock surges on 25% revenue growth and 32% EBITDA margin. It raises 2025 outlook as it scales with disciplined cost control.

BTSG surges with 33% infusion growth and stronger EPS gains, making it a more compelling pick than OPCH right now.

BTSG surges with 33% infusion growth and stronger EPS gains, making it a more compelling pick than OPCH right now.

AYI surges on strong Q3 results as acquisitions and tech-driven segments power 23% EPS growth and margin gains.